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We describe 58 adult patients with melioidosis in 
Cambodia (2007–2010). Diabetes was the main risk factor 
(57%); 67% of infections occurred during the rainy season. 
Bloodstream infection was present in 67% of patients, which 
represents 12% of all bloodstream infections. The case-
fatality rate was 52% and associated with inappropriate 
empiric treatment. 
M
elioidosis, an infectious disease caused by 
Burkholderia pseudomallei, is endemic to Southeast 
Asia and tropical Australia (1,2).  B. pseudomallei is a 
gram-negative bacterium that causes lung or soft tissue 
infections with or without bloodstream infection (BSI) (3); 
the case-fatality rate can exceed 80%. Treatment includes 
third-generation cephalosporins or carbapenems, followed 
by maintenance courses of sulfamethoxazole/trimethoprim 
(SMX/TMP) with or without doxycycline.
In Cambodia, few microbiologically conﬁ  rmed cases 
have been described (4–7). We describe 58 adult patients 
in whom melioidosis was diagnosed during July 1, 2007–
January 31, 2010, at Sihanouk Hospital Centre of Hope, 
Phnom Penh, Cambodia.
The Study
Melioidosis was deﬁ  ned as growth of B. pseudomallei 
from any clinical specimen (blood, pus, or urine). 
Nonfermentative gram-negative rods suspected for 
B. pseudomallei (wrinkled colonies, oxidase positive, 
polymyxin and gentamicin resistant, amoxicillin/
clavulanic acid susceptible [8]) were identiﬁ   ed by the 
API 20NE system (bioMérieux, Marcy L’Etoile, France). 
MICs were determined with Etest (Biodisk, Solna, 
Sweden). Interpretive criteria were those deﬁ  ned for B. 
pseudomallei by the Clinical and Laboratory Standards 
Institute (9).
Recurrences were deﬁ   ned as the culture-conﬁ  rmed 
reappearance of symptoms after initial response to therapy 
(10). Treatment was considered appropriate if it contained 
ceftazidime, a carbapenem, or amoxicillin/clavulanic acid 
with or without SMX/TMP.
Risk factors were assessed by univariate analysis. 
Ethical approval was granted by the University Hospital 
Antwerp and the National Ethical Committee in Phnom 
Penh.
Seventy-one isolates of B. pseudomallei were 
recovered from 58 patients (mean age 49 years, range 
18–73 years); 34 (59%) were men. Seasonal patterns of 
infection are shown in Figure 1 and geographic distribution 
of patients’ homes (56) in Figure 2. Melioidosis was 
diagnosed in 39 (67%) patients during the rainy season. 
In 39 patients, B. pseudomallei was recovered from blood 
samples, which represented 12.0% of the 328 clinically 
signiﬁ  cant organisms from BSIs and 1.0% of the 3,976 
systemic inﬂ  ammatory response syndrome episodes during 
the study. In 2 patients, melioidosis was retrospectively 
considered a recurrence 137 and 231 days postinfection.
Fifty-four (52 initial and 2 successive) isolates were 
used for resistance testing (Table 1). No resistance was 
noted for ceftazidime, meropenem, amoxicillin/clavulanic 
acid or doxycycline, but 12 (22.2%) isolates had MICs 
equal to the susceptibility breakpoint for chloramphenicol.
Risk factor information available for 51 patients 
included diabetes mellitus (34 [59%] patients); alcoholism 
(7 [12%]); and corticosteroid use (3 [5%]). Most (39) 
patients had BSI with or without pneumonia. Median delay 
to growth of blood cultures was 4 days (range 2–8). During 
the study, B. pseudomallei was increasingly recovered 
from nonblood specimens, in line with growing laboratory 
expertise. Involvement of the lungs was noted in 28 (48%) 
patients. Other sites included skin and soft tissue (17 
patients), bone and joints (8), urogenital tract (4), spleen 
(8), liver (5), and psoas muscle and thyroid gland (1 each). 
Infection was often multifocal. Seventeen (29%) patients 
had shock or multiorgan failure. The median delay from 
symptom onset to seeking treatment was 28 days (range 
1–730 days).
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Figure 1. Number of patients in whom melioidosis was diagnosed, 
by season, Phnom Penh, Cambodia, July 1, 2007–January 31, 
2010.Thirty (52%) patients died; no outcome data were 
available for 3 patients. Death occurred early; 19 (63%) 
nonsurvivors died within 1 week after admission. In 
univariate analysis, risk factors for death were signs 
of shock, multiorgan failure, or BSI and not receiving 
appropriate empiric therapy (Table 2). Among the 25 
survivors, 22 (88%) recovered without recurrence; the other 
3 were lost to follow-up during maintenance treatment. The 
mean duration of follow-up was 12.8 months (range 3.5–28 
months).
Treatment data were available for 53 patients; 18 
(34%) received inappropriate empiric therapy; all died 
early. Thirty-ﬁ  ve patients received appropriate treatment; 
23 patients were given ceftazidime (2 g 3×/d for >14 days) 
with or without SMX/TMP (30 mg/kg 2×/d), 6 received 
amoxicillin–clavulanic acid (875–1,000 mg 3×/d) with or 
without SMX/TMP, and another 6 received SMX/TMP 
with doxycycline (200 mg 1×/d). Twenty-three patients 
continued maintenance therapy, primarily SMX/TMP 
with or without doxycycline (22 patients). Total treatment 
duration ranged from 3 to 6 months.
Conclusions
Our ﬁ  ndings of melioidosis in 58 adults complement 
the recently published data on melioidosis in children in 
Cambodia (7). A limitation of our study is its retrospective 
nature; a small number of patients precluded detailed 
study of risk factors and calculation of population-based 
incidence data. In addition, we have not yet studied the 
isolates to the genetic level. However, presently used 
phenotypic characteristics have been validated against 
molecular reference standards as accurate tools for B. 
pseudomallei identiﬁ  cation (8).
Risk factors for patients and epidemiologic proﬁ  les 
were similar to those observed in northeastern Thailand 
(1,11). Most cases occurred during or shortly after the 
rainy season (May–November); diabetes mellitus was the 
most relevant risk factor, which is consistent with ﬁ  ndings 
from other regions where melioidosis is endemic (1,11,12). 
Diabetes is quickly emerging in Cambodia and remains a 
difﬁ  cult-to-treat chronic disease in poor rural settings (13).
In this study, nearly two thirds of patients had BSI and 
half had pneumonia. These data are consistent with studies 
from Thailand and Australia, where BSI and pneumonia 
accounted for 46%–60% and 50%–60% of manifestations, 
respectively (11,12). Soft tissue and deep organ abscesses 
were also frequent. The ﬁ  nding of a spleen abscess in a 
melioidosis-endemic area should trigger suspicion of 
melioidosis.
In our study, distinguishing  primary infection or 
reinfection from relapse was not possible, but the seasonal 
link suggests recent infections. The 2 recurrences in our 
study were probably relapses caused by insufﬁ  cient 
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Table 1. MICs for 54 Burkholderia pseudomallei isolates, Phnom Penh, Cambodia, July 1, 2007–January 31, 2010* 
Antimicrobial drug 
MIC, μg/mL 
MIC50 MIC90
Breakpoints,
μg/mL
0.38 0.5 0.75 1 1.5 2 3 4 6 8 S R
Meropenem 3 29 16 1 3 2 – – – – 0.5 1.5 <4> 16
Doxycycline† – 13 19 18 3 1 – – – – 0.75 1 <4> 16
Ceftazidime† – 2 0 18 25 7 2 – – – 1.5 2 <8> 32
Amoxicillin/ 
clavulanic acid 
–10 1 3 3 0 7 2 1 – – 1 . 5 2 < 8> 32
Chloramphenicol ––––11 0 1 7 1 6 1 2 68 < 8> 32
0.032 0.038 0.047 0.064 0.094 0.125 0.19 0.25 0.38 0.75 1 1.5 3
Sulfamethoxazole/ 
trimethoprim 
3 1 7 12 5 9 4 7 1 1 3 1 0 0.125 0.75 <2> 4
*MICs determined by Etest (AB Biodisk, Solna, Sweden). MIC50, MIC for 50% of isolates; MIC90, MIC for 90% of isolates; S, susceptible; R, resistant; –, 
no isolates with this MIC. 
†53 isolates included. 
Figure 2. Map of Cambodia with geographic origin of the 58 patients 
with melioidosis diagnosed during July 1, 2007–January 31, 2010.Melioidosis, Phnom Penh, Cambodia
treatment of the ﬁ  rst (unrecognized) episode, as has been 
described in patients in Thailand and Australia (10). The 
possibility of relapse emphasizes the need for intense 
follow-up during and after the treatment course.
We noted a high case-fatality rate, especially among 
patients with BSI or pneumonia, who were in shock or had 
multiorgan failure, or who were receiving inappropriate 
empirical therapy. Potential interventions to decrease risk 
factors for death caused by melioidosis include improved 
sepsis care and ensured availability of effective drugs such 
as ceftazidime, carbapenems, and amoxicillin/clavulanic 
acid. Although we did not demonstrate resistance to any 
of these antimicrobial drugs, resistance can occur during 
therapy; follow-up blood cultures during treatment is 
essential (14).
During the 19-month study, we observed a learning 
curve on melioidosis at several levels in the hospital. 
Even though melioidosis is well known in the Southeast 
Asian region (2), it was unfamiliar to most clinicians and 
laboratory staff at the start of the study. Our ﬁ  ndings may 
also have an effect at the national level, especially regarding 
early diagnosis and treatment. Awareness must be raised 
among health care workers and high-risk patient groups 
(e.g., diabetes patients). Development of quality-assured 
and affordable microbiological capacity throughout the 
country is also crucial in the broader picture of surveillance 
and containment of antimicrobial drug resistance. Careful 
adaption of local treatment guidelines is essential and has 
been successful in other settings, e.g., Northern Territory, 
Australia (15). Because melioidosis appears endemic to 
Cambodia, the public health impact of this disease warrants 
further research and action. 
The Bloodstream Infection Surveillance Project was 
supported by Project 2.08 of the third framework agreement 
between the Belgian Directorate General of Development 
Cooperation and the Institute of Tropical Medicine, Antwerp, 
Belgium.
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Department of Clinical Sciences, Institute of Tropical Medicine 
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Table 2. Predictors of death for 55 patients with melioidosis, Phnom Penh, Cambodia, July 1, 2007–January 31, 2010* 
Risk factor 
Presence of 
risk factor 
No.
patients
No. patients 
who died  Relative risk (95% CI)   p value 
Age >55 y  Y 24 14 1.13 (0.70–1.83)  0.786 
N3 11 6
Male sex  Y 31 18 1.16 (0.70–1.91)  0.595 
N2 41 2
Rainy season  Y 36 23 1.73 (0.92–3.28)  0.087 
N1 97
Diabetes Y 32 14 0.70 (0.41–1.21) 0.359 
N1 61 0
Alcoholism Y 7 6 0.97 (1.19–3.22)  0.092 
N3 21 4
Clinical sign 
  Duration of symptoms <2 mo  Y 12 3 2.26 (0.80–6.42)  0.152 
N2 31 3
  Bloodstream infection  Y 37 28 6.81 (1.82–25.50)  <0.001 
N1 82
 Pneumonia  Y 28 18 1.52  (0.90–2.57)  0.172 
N2 61 1
  Deep abscesses  Y 15 6 0.80 (0.38–1.67)  0.742 
N2 41 2
  Bone/joint infection  Y 8 4 1.04 (0.47–2.28)  1.000 
N2 91 4
  Urogenital infection  Y 5 1  0.38 (0.64–2.25)  0.345 
N3 82 0
  Skin and soft tissue infection  Y 19 6 0.48 (0.24–0.97)  0.023 
N3 52 3
  Shock or multiorgan failure  Y 17 13 4.59 (1.60–13.32)  <0.001 
N1 83
Therapy 
  Inappropriate empiric therapy  Y 18 18 3.50 (2.07–5.90)  <0.001 
N3 51 0
*Not all information about outcome predictors was available from all patients. Fisher exact test was used for categorical variables and Student t test for 
continuous variables. CI, confidence interval. Statistically significant associations (p<0.05) are shown in boldface.University Hospital, Antwerp. Her research interests include 
bacterial infections and antimicrobial drug resistance in tropical 
low-resource settings.
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